Champions Oncology vs Recursion Pharmaceuticals
CSBR and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSBR and RXRX compare
Recursion Pharmaceuticals is the larger company, worth 29 times as much as Champions Oncology ($1.9B against $66.5M).
Recursion Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 6.7% for Champions Oncology).
Champions Oncology keeps more of each dollar of sales as profit, with a net margin of −1.8% compared with −697% at Recursion Pharmaceuticals.
Champions Oncology scores higher on the StockData Score (9 against 8 for Recursion Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSBR | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | $66.5M | $1.9B |
| Share price | $4.78 | $3.59 |
| Change, 1 year | −29.5% | −20.4% |
| Change, 5 years | −49.0% | −81.9% |
| Beta (5Y) | 0.36 | 2.68 |
| Employees | 214 | 50 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 28.2× |
| P/B | 17.1× | 2.1× (better) |
| EV/EBITDA | 216× | – |
| FCF yield | −9.2% (better) | −16.3% |
| Fair value | $1.36 | $3.23 |
| Margin of safety | −251% | −11.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.7% | 56.2% (better) |
| Revenue growth, 5Y average | 7.7% | 79.9% (better) |
| Net income growth (TTM) | −138% | – |
| EPS growth (TTM) | −140% | – |
| Profitability | ||
| Gross margin | 49.8% (better) | 29.2% |
| Operating margin | −1.7% (better) | −725% |
| Net margin | −1.8% (better) | −697% |
| FCF margin | −10.1% (better) | −458% |
| Return on equity | −29.8% (better) | −48.7% |
| Return on invested capital | – | −102% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Interest coverage | – | −541.6× |
| Current ratio | 1.03 | 5.01 (better) |
| Altman Z-score | −0.30 | 0.05 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −11.4% |
| Shareholder yield | 0.00% (better) | −11.4% |
| Ownership | ||
| Held by institutions | 42.4% | 67.6% |
| Held by insiders | 30.5% | 5.6% |
| Insider net buying, 12 months | – | −$7.4M |
| Short interest, % of float | 0.75% | 28.2% |
Go deeper
- CSBR stock overview
- CSBR income statement
- CSBR valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.